See more : iA Financial Corporation Inc. (IAF-PI.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Joinn Laboratories(China)Co.,Ltd. (6127.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Joinn Laboratories(China)Co.,Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- PT Lippo General Insurance Tbk (LPGI.JK) Income Statement Analysis – Financial Results
- Horizon Bancorp, Inc. (HBNC) Income Statement Analysis – Financial Results
- Zimmer Biomet Holdings, Inc. (ZBH.SW) Income Statement Analysis – Financial Results
- Universal Store Holdings Limited (UNI.AX) Income Statement Analysis – Financial Results
- Cho Thavee Public Company Limited (CHO.BK) Income Statement Analysis – Financial Results
Joinn Laboratories(China)Co.,Ltd. (6127.HK)
About Joinn Laboratories(China)Co.,Ltd.
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.27B | 1.52B | 1.08B | 639.38M | 408.80M | 301.28M | 241.81M | 206.61M | 184.81M | 143.83M | 97.39M |
| Cost of Revenue | 1.36B | 1.18B | 777.56M | 523.09M | 302.82M | 192.05M | 131.76M | 119.79M | 100.13M | 86.51M | 71.29M | 49.82M |
| Gross Profit | 1.01B | 1.09B | 739.12M | 552.81M | 336.56M | 216.75M | 169.52M | 122.01M | 106.47M | 98.30M | 72.54M | 47.56M |
| Gross Profit Ratio | 42.62% | 47.90% | 48.73% | 51.38% | 52.64% | 53.02% | 56.27% | 50.46% | 51.53% | 53.19% | 50.43% | 48.84% |
| Research & Development | 96.89M | 77.98M | 47.76M | 50.66M | 39.63M | 23.69M | 25.58M | 13.83M | 10.49M | 10.50M | 14.63M | 11.95M |
| General & Administrative | 89.01M | 78.43M | 96.53M | 84.64M | 43.15M | 42.40M | 28.05M | 23.83M | 19.62M | 13.83M | 43.80M | 36.49M |
| Selling & Marketing | 11.79M | 18.01M | 15.97M | 12.91M | 12.47M | 6.63M | 5.75M | 4.38M | 3.13M | 2.00M | 1.83M | 972.66K |
| SG&A | 100.80M | 96.44M | 112.51M | 97.55M | 55.62M | 49.03M | 33.80M | 28.21M | 22.75M | 15.83M | 45.63M | 37.47M |
| Other Expenses | 308.04M | 194.72M | 126.92M | 102.81M | 38.55M | 1.85M | -759.80K | 7.54M | 10.78M | 16.42M | 9.88M | 8.87M |
| Operating Expenses | 505.69M | 369.14M | 287.18M | 251.01M | 133.79M | 101.09M | 77.17M | 68.58M | 58.43M | 46.98M | 46.98M | 40.90M |
| Cost & Expenses | 1.87B | 1.55B | 1.06B | 774.11M | 436.61M | 293.14M | 208.92M | 188.38M | 158.57M | 133.50M | 118.28M | 90.72M |
| Interest Income | 142.50M | 131.23M | 83.72M | 2.08M | 1.89M | 2.26M | 1.80M | 199.36K | 129.13K | 106.43K | 0.00 | 8.33M |
| Interest Expense | 3.44M | 3.58M | 3.96M | 836.50K | 47.58K | 89.67K | 20.63K | 8.91K | 1.21M | 3.67M | 5.64M | 0.00 |
| Depreciation & Amortization | 129.51M | 120.96M | 96.44M | 60.65M | 42.37M | 29.06M | 26.20M | 27.10M | 23.86M | 20.54M | 9.65M | 8.56M |
| EBITDA | 639.52M | 1.36B | 712.94M | 422.06M | 257.87M | 156.91M | 119.63M | 88.12M | 82.76M | 70.79M | 28.50M | 19.39M |
| EBITDA Ratio | 26.91% | 60.42% | 47.01% | 38.71% | 40.69% | 38.78% | 40.03% | 36.75% | 40.18% | 47.63% | 19.82% | 6.84% |
| Operating Income | 507.10M | 1.23B | 642.89M | 361.12M | 206.14M | 126.01M | 94.18M | 53.55M | 46.99M | 46.33M | 18.86M | -1.89M |
| Operating Income Ratio | 21.34% | 54.04% | 42.39% | 33.56% | 32.24% | 30.82% | 31.26% | 22.14% | 22.74% | 25.07% | 13.11% | -1.94% |
| Total Other Income/Expenses | -145.88K | 14.36M | -885.48K | -545.98K | -252.97K | 1.85M | -759.80K | 7.46M | 10.69M | 16.19M | 7.51M | 296.53K |
| Income Before Tax | 506.95M | 1.24B | 642.00M | 360.57M | 205.89M | 127.86M | 93.42M | 61.01M | 57.68M | 62.53M | 26.36M | 6.96M |
| Income Before Tax Ratio | 21.33% | 54.67% | 42.33% | 33.51% | 32.20% | 31.28% | 31.01% | 25.23% | 27.92% | 33.83% | 18.33% | 7.15% |
| Income Tax Expense | 115.40M | 166.80M | 85.59M | 46.94M | 27.68M | 19.67M | 16.97M | 9.32M | 8.51M | 13.53M | 4.08M | -2.66M |
| Net Income | 396.99M | 1.07B | 557.46M | 315.01M | 178.37M | 108.34M | 76.45M | 51.69M | 49.17M | 49.00M | 22.29M | 9.63M |
| Net Income Ratio | 16.71% | 47.37% | 36.76% | 29.28% | 27.90% | 26.50% | 25.37% | 21.38% | 23.80% | 26.51% | 15.50% | 9.88% |
| EPS | 0.53 | 2.01 | 0.77 | 0.51 | 0.29 | 0.17 | 0.15 | 0.11 | 0.11 | 0.11 | 0.05 | 0.02 |
| EPS Diluted | 0.53 | 2.00 | 0.76 | 0.51 | 0.29 | 0.17 | 0.15 | 0.11 | 0.11 | 0.11 | 0.05 | 0.02 |
| Weighted Avg Shares Out | 749.04M | 537.13M | 722.63M | 617.43M | 617.42M | 621.18M | 513.93M | 463.19M | 462.82M | 461.15M | 466.17M | 451.90M |
| Weighted Avg Shares Out (Dil) | 749.04M | 537.13M | 729.39M | 623.66M | 617.46M | 621.18M | 513.93M | 463.36M | 462.82M | 461.15M | 466.17M | 452.97M |
Source: https://incomestatements.info
Category: Stock Reports